Liver disease biotech Galmed sets terms for $31 million IPO


Shutterstock photo

Galmed Pharmaceuticals, a clinical-stage biotech developing therapies for liver diseases and gallstones, announced terms for its IPO on Friday. The Tel Aviv, Israel-based company plans to raise $31 million by offering 2.4 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Galmed Pharmaceuticals would command a fully diluted market value of $148 million.

Galmed Pharmaceuticals, which was founded in 2000, plans to list on the NASDAQ under the symbol GLMD. Galmed Pharmaceuticals initially filed confidentially on December 31, 2013. Maxim Group is the sole bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by